



## Immunological Implications in Neuromuscular Disorders

Guest Editors:

### **Dr. Filippo Brighina**

Department of Biomedicine,  
Neuroscience and advanced  
Diagnostics (BIND), University of  
Palermo, Via del Vespro 143,  
90129 Palermo, Italy

### **Dr. Vincenzo Di Stefano**

Department of Biomedicine,  
Neuroscience and advanced  
Diagnostics (BIND), University of  
Palermo, Via del Vespro 143,  
90129 Palermo, Italy

Deadline for manuscript  
submissions:

**closed (5 December 2023)**

### Message from the Guest Editors

In the last fifty years, our knowledge has rapidly grown on immunology and immunological aspects of neuromuscular disorders. Indeed, available antibody tests for many autoimmune conditions have driven growing interest in autoimmunity, as well as the possibility to effectively treat patients affected by the autoimmune disease through new developed and emerging target therapies (i.e., Rituximab, Eculizumab, etc.) for the treatment of Myasthenia Gravis and Chronic inflammatory Demyelinating Polyradiculoneuropathy. On the other side, the description of an immunological basis with specific diagnostic antibody testing for relevant conditions such as “Stiff person syndrome”, “Isaacs syndrome” and other “paraneoplastic syndromes”, might have contributed to this revolution.

Papers on targets therapies (Rituximab, Eculizumab, other monoclonal antibodies for autoimmune neuromuscular disorders) or Immune Checkpoint Inhibitors in malignancies are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Stephen D. Meriney

Department of Neuroscience,  
University of Pittsburgh,  
Pittsburgh, PA 15260, USA

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, CAPus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2023).

## Contact Us

Brain Sciences Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/brainsci](http://mdpi.com/journal/brainsci)  
[brainsci@mdpi.com](mailto:brainsci@mdpi.com)  
[X@BrainSci\\_MDPI](https://twitter.com/BrainSci_MDPI)